Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Cadila Healthcare Ltd    CADILAHC   INE010B01027

CADILA HEALTHCARE LTD (CADILAHC)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Cadila Healthcare : gets Mexico regulator approval for Lipaglyn

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 07:58pm CET

Cadila Healthcare Ltd is currently trading at Rs 465, down by Rs 13.65 or 2.85% from its previous closing of Rs 478.65 on the BSE. Zydus today announced that the Mexico regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval to commercialize Lipagly (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.

Elevated triglycerides and insulin resistance are two key components of the metabolic syndrome, which medical science believes are responsible for diseases like hypertriglyceridemia, diabetic dyslipidemia or Non-Alcoholic Steatohepatitis disease (NASH). Increased triglyceride accumulation in the liver can also lead to inflammation, fibrosis, cirrhosis and liver failure, a serious medical condition known as NAFLD or NASH. Additionally, Zydus is currently evaluating Saroglitazar in several clinical trials for treating liver conditions like NASH and Primary Biliary Cholangitis (PBC).

"Saroglitazar is an important scientific and medical breakthrough in our effort to develop medicines for patients suffering from hypertriglyceridemia and diabetic dyslipidemia", said Pankaj Patel, Chairman, Zydus Group, and added, "This approval of Saroglitazar in Mexico is a major milestone for the company."

Cadila Healthcare Ltd is currently trading at Rs 465, down by Rs 13.65 or 2.85% from its previous closing of Rs 478.65 on the BSE. The scrip opened at Rs 476 and has touched a high and low of Rs 478 and Rs 464.5 respectively.

(c) 2017India Infoline Ltd. All rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CADILA HEALTHCARE LTD
02/12CADILA HEALTHCARE : Cadila Healthcare's Moraiya facility successfully completes ..
AQ
02/12AJANTA PHARMA : Cadila, Ajanta reports successful USFDA inspection
AQ
02/10CADILA HEALTHCARE LTD'S Q3FY18 CONSO : Beats Estimates
AQ
02/10CADILA HEALTHCARE : Zydus cadila expects us to contribute 60% of revenues by fy2..
AQ
02/09CADILA HEALTHCARE : Q3 PAT grows 68% as US biz jumps 78% on flu drug sales
AQ
02/09CADILA HEALTHCARE : Net profit jumps 68% in dec quarter
AQ
02/09CADILA HEALTHCARE : Standalone net leaps
AQ
02/07CADILA HEALTHCARE : down 2.5% on surprise audit of Moraiya facility
AQ
02/02CADILA HEALTHCARE LIMITED : - Analysts/Institutional Investor Meet/Con. Call Upd..
AQ
01/25CADILA HEALTHCARE : Turns focus on vaccines, biosimilars
AQ
More news
Financials ( INR)
Sales 2018 117 B
EBIT 2018 22 656 M
Net income 2018 17 913 M
Debt 2018 27 107 M
Yield 2018 0,93%
P/E ratio 2018 23,76
P/E ratio 2019 19,53
EV / Sales 2018 3,81x
EV / Sales 2019 3,38x
Capitalization 419 B
Chart CADILA HEALTHCARE LTD
Duration : Period :
Cadila Healthcare Ltd Technical Analysis Chart | CADILAHC | INE010B01027 | 4-Traders
Technical analysis trends CADILA HEALTHCARE LTD
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 38
Average target price 484  INR
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Sharvil Pankajbhai Patel Joint Managing Director & Executive Director
Pankaj Ramanbhai Patel Executive Chairman & Joint Managing Director
Ganesh Narayan Nayak Chief Operating Officer & Executive Director
Nitin Dalsukhrai Parekh Chief Financial Officer
Humayun Raja Dhanrajgir Independent Non-Executive Director
Sector and Competitors